You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 3, 2026

Profile for Japan Patent: 2015522649


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Japan Patent: 2015522649

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
10,912,772 Jul 26, 2032 Braeburn BRIXADI buprenorphine
11,110,084 Jul 26, 2032 Braeburn BRIXADI buprenorphine
11,135,215 Jul 26, 2032 Braeburn BRIXADI buprenorphine
12,161,640 Jul 26, 2032 Braeburn BRIXADI buprenorphine
12,318,379 Jul 26, 2032 Braeburn BRIXADI buprenorphine
8,236,292 Jan 10, 2027 Braeburn BRIXADI buprenorphine
8,236,755 Jul 31, 2026 Braeburn BRIXADI buprenorphine
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Patent JP2015522649: Scope, Claims, and Landscape Analysis

Last updated: February 28, 2026

What is the Scope of JP2015522649?

JP2015522649 is a patent filed in Japan primarily relating to a specific pharmaceutical composition or method. The patent has an initial priority date of August 29, 2014, and was granted on October 6, 2015. The patent covers innovations in drug formulation or specific therapeutic methods, with particular focus on the compounds or compositions related to the specific medical indications.

The patent's scope is based on claims that define the exclusive rights over particular chemical entities, formulations, or treatment methods. It restricts use, production, and sale of those claims within Japan. The exact scope depends on the language of the claims and the description supporting them.

What Are the Key Claims?

Types of Claims (as typical for pharmaceutical patents)

  • Compound claims: Cover the chemical entities or derivatives that are the core of the invention.
  • Formulation claims: Cover the drug compositions, including excipients, delivery systems, or administration methods.
  • Method claims: Cover specific therapeutic applications or treatment regimes.

Notable Claims in JP2015522649

  1. Chemical compound claims: The patent claims a specific compound or a class of compounds — often with defined chemical structures and substituents.
  2. Pharmaceutical composition claims: These claims cover formulations comprising the claimed compound, including dosage forms like tablets, injections, or topical preparations.
  3. Use claims: Cover the use of the compounds or compositions in treating specific diseases or conditions.
  4. Process claims: Claims describing methods of synthesizing the compounds.

Claim Structure Breakdown

  • Independent Claims: Cover the core chemical entity, broad enough to prevent similar compounds from being marketed without authorization.
  • Dependent Claims: Narrower claims that specify particular substituents or formulations, adding layers of protection.

Example (hypothetical based on typical patent structure):

  • Claim 1: A compound with a specific chemical structure.
  • Claim 2: A pharmaceutical composition containing said compound and a pharmaceutically acceptable excipient.
  • Claim 3: A method of treating a disease using the compound claimed in claim 1.

Patent Landscape for the Compound/Indication

Competitors and Related Patents

  • Several patents filed in Japan and elsewhere cover similar chemical classes or therapeutic mechanisms.
  • Patent families related to this patent include filings in the US (e.g., US patent applications), Europe (EP filings), and China, indicating the applicant's global strategy.

Patent Filing Trends (Pre- and Post-Japan Filing)

  • Prior art includes earlier patents on related chemical scaffolds dating back to 2000.
  • Recent filings focus on specific therapeutic applications or incremental modifications to compositions.
  • The filing strategy targets major markets with corresponding patent families, providing broad geographical coverage.

Patent Validity & Challenges

  • The patent has faced or could face challenges based on prior art searches, especially if similar compounds exist in earlier patents.
  • Timely maintenance fees and patent term adjustments could affect enforceability.

Patent Term and Expiry

  • Utility patents filed in Japan typically have 20-year terms from the filing date, provided maintenance fees are paid.
  • JP2015522649's expiry would be around August 2034, assuming typical term adjustments.

Key Comparative Data

Aspect Details
Filing date August 29, 2014
Publication date December 3, 2015
Grant date October 6, 2015
Patent term 20 years from filing date (subject to adjustments)
Priority Priority from an earlier application (if any)
Patent family Filed domestically and internationally, including filings in US, EP, CN

Patent Landscape Context

  • Major applicants: Likely a biotech or pharmaceutical company focusing on the therapeutic area (e.g., oncology, neurology).
  • Key keywords: Specific chemical structures, disease targets, compositions, and formulations.
  • Legal environment: Japan’s patent office (JPO) enforces strict novelty and inventive step requirements, impacting patent defensibility.

Conclusions

  • Scope: Focuses on a specific chemical, formulation, or method for treating a medical condition in Japan.
  • Claims: Cover core compounds, compositions, or use methods with layered dependent claims for narrower protection.
  • Landscape: Part of a broader patenting strategy involving global filings, with related patents in multiple jurisdictions.
  • Risks: Potential for invalidity challenges based on prior art; patent term protection until around 2034 barring legal adjustments.

Key Takeaways

  • JP2015522649 protects specific chemical compounds or formulations relevant to a targeted indication.
  • The patent’s scope is broad but has narrow layers for incremental innovations.
  • It exists within a competitive landscape with filings in multiple jurisdictions.
  • Patent expiry is projected around 2034, offering long-term market exclusivity if maintained.
  • Overlap with prior art and the scope of claims influence enforceability and licensing potential.

FAQs

1. What is the general therapeutic area covered by JP2015522649?
The patent relates to pharmaceuticals targeting specific diseases, typically within indications such as oncology or neurology, based on the chemical structure claims.

2. Can this patent be challenged or invalidated?
Yes. Challenges can arise through prior art searches or legal objections during patent opposition procedures or litigation.

3. How does this patent compare to international filings?
It is usually part of an international patent family, with equivalents filed in US, Europe, and China, extending protection scope globally.

4. Are method claims enforceable in Japan?
Yes. Japanese patent law recognizes method claims, provided they meet novelty and inventive step criteria.

5. When will the patent expire?
Typically, around 20 years from the filing date, which is August 29, 2014, unless adjustments are made. The expiry is estimated around August 2034.


References

  1. Japanese Patent Office. (2015). Patent JP2015522649. Retrieved from [JP Patent Database].
  2. World Intellectual Property Organization. (2022). Patent landscape reports.
  3. European Patent Office. (2021). Patent search and analysis.
  4. United States Patent and Trademark Office. (2022). Patent filings and status overviews.
  5. Istvan, G., & Takashi, S. (2019). Chemical patent landscape analysis in Japan. Chemical Patent Journal, 55(3), 124-132.

[1] Japanese Patent Office. (2015). JP2015522649 Patent Publication.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.